Please ensure Javascript is enabled for purposes of website accessibility

Up 81.6%: Is Dynavax Technologies Corporation Stock Still a Buy?

By George Budwell - Jul 31, 2017 at 8:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dynavax's shares are rocketing higher after a positive advisory committee vote for Heplisav-B.

What happened

Dynavax Technologies Corporation (DVAX -2.10%) stock jumped a whopping 81.6% in after-hours trading Friday because of a favorable 12-to-1 advisory committee vote for its experimental hepatitis-B vaccine, Heplisav-B. This panel of independent experts was charged with assessing the vaccine's safety profile for the U.S. Food and Drug Administration, which they deemed sufficient to warrant approval. As the FDA only rarely goes against the advice of its advisory committees, Dynavax appears to be a near lock to gain its first regulatory approval, and finally transition into a commercial-stage company.  

Miniature rocket taking flight from a person's hand.

Image source: Getty Images.

So what

The outcome of this critical vote was in serious doubt after the FDA released its briefing documents last Wednesday. Specifically, the agency pointed out that patients receiving Heplisav-B exhibited a higher rate of serious adverse effects in its latest phase 3 trial, compared with those receiving GlaxoSmthKline's Engerix-B. Although the data was far from conclusive, this safety concern was enough to cause Dynavax's shares to nosedive by double digits. 

Now what

The FDA is expected to hand down a regulatory decision for Heplisav-B by Aug. 10. If approved, this vaccine has the potential to become the new standard of care for hepatitis-B in adults, which should translate into peak sales in the neighborhood of $700 million per year.

As vaccine-makers are highly coveted because of the commercial longevity of their products, Dynavax has a real shot at eventually garnering a top-notch premium in the area of something along the lines of 5 times Heplisav-B's peak sales, assuming approval. In other words, this quantum leap in Dynavax's valuation may only be just the beginning of a long-tailed growth trend for the company.

So while there's still some regulatory risk on the table, and commercial launches rarely go according to plan, this small-cap biotech stock could prove to be a tremendous growth vehicle. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
$16.34 (-2.10%) $0.35
GSK Stock Quote
$36.03 (0.84%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.